Five Interesting Studies Using Real-World Data in Oncology
- Colin Pfeiffer
- Apr 22, 2020
- 2 min read
Efficacy and Safety of Bevacizumab Combined with First-Line Chemotherapy in Elderly (≥75 Years) Patients with Metastatic Colorectal Cancer: A Real-World Study.
Summary: Elderly patients are often underrepresented in standard clinical trials. 402 French colorectal cancer patients, all over the age of 75, were included in the analysis. Data was sourced from physicians randomly selected from a national database. Most patients were treated with either FOLFOX or FOLFIRI + bevacizumab. Median progression-free survival was estimated at 9.1 months, while 79% of patients experienced disease progression. Bevacizumab-specific AEs were reported in 17% of patients.
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
Summary: A study team used Canadian provincial drug registries to find 329 patients with metastatic melanoma who were receiving second-line treatment. Since the data was robustly linked, the researchers could adjust for potential confounders using propensity scores. Patients treated with second-line ipilimumab saw overall survival of 7.2 months, compared to control patients (non-ipilumumab therapies) with 4.9 months. However, median overall survival in ipilimumab patients was 2.9 months shorter in the real-world data when compared to the pivotal trial’s data (7.2 vs 10.1 mos).
Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center
Summary: 108 patient profiles, all with multiple myeloma treated by bortezomib, were pulled from the National University Cancer Institute in Singapore. 88% had received antibiotic prophylaxis with Bactrim for Pneumocystis Carinii infection and none received a fluoroquinolone due to high resistance rates in Asian regions. In the first 12 weeks of bortezomib-based induction therapy, 25 patients experienced febrile neutropenia, 23 were hospitalized, and all patients recovered. Febrile neutropenia episodes were associated with lower ANC (p = 0.036), renal impairment (p = 0.013), and ISS stage (p = 0.026).
Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy.
Summary: 66 women with Stage III/IV ovarian cancer were retrospectively examined from Montreal’s McGill University Health Center data. First chemotherapy treatments cost an average of CAD $52,527, with second and third relapses increasing costs by 38% and 86%. Costs were also higher for platinum-resistant disease. Median survival for second relapse was 50.7 months and 42.8 months for third relapse. After the third relapse, healthcare costs increased dramatically while patient survival time decreased.
Efficacy and Safety of Nivolumab in Previously Treated Patients with Non-Small-cell Lung Cancer: Real World Experience in Argentina.
Summary: In 104 Argentinean patients, second-line nivolumab use saw a 78.9% drug-related toxicity rate, with 33.9% of patients requiring corticosteroids. 2% of patients experienced complete response, 28% partial response, 32% stable disease, and 39% progressive disease. Longer progression-free survival was associated with Toxicity Grades I-III (p = 0.08) and age younger than 50 years (p = 0.001)
Comments